Disease · MONDO_0056806
Comparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 19 of 19
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| PF-06439535 vs Bevacizumab-EU: Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality) | 303 of 342 | 304 of 348 | 690 | NCT02364999 | Trial comparisons |
| MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin®: deaths from any cause | 23 of 311 | 24 of 310 | 621 | NCT03296163 | Trial comparisons |
| MB02 (Bevacizumab Biosimilar Drug) vs EU-approved Avastin®: serious adverse events | 58 of 311 | 54 of 310 | 621 | NCT03296163 | Trial comparisons |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: deaths from any cause | 211 of 287 | 201 of 285 | 572 | NCT02409342 | Trial comparisons |
| Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine) vs Atezolizumab: serious adverse events | 77 of 263 | 97 of 286 | 549 | NCT02409342 | Trial comparisons |
| Sintilimab vs Docetaxel: deaths from any cause | 108 of 144 | 101 of 130 | 274 | NCT03150875 | Trial comparisons |
| Sintilimab vs Docetaxel: serious adverse events | 56 of 144 | 34 of 130 | 274 | NCT03150875 | Trial comparisons |
| Crizotinib vs Chemotherapy: deaths from any cause | 62 of 104 | 61 of 101 | 205 | NCT01639001 | Trial comparisons |
| Crizotinib vs Chemotherapy: serious adverse events | 46 of 104 | 13 of 101 | 205 | NCT01639001 | Trial comparisons |
| Lenvatinib vs Lenvatinib Matched Placebo: serious adverse events | 46 of 89 | 21 of 46 | 135 | NCT01529112 | Trial comparisons |
Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) vs Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC): Arm 3 and 4: Number of Participants Who Discontinued Study Treatment Due to an AE | 2 of 10 | 6 of 41 | 51 | NCT03396445 | Trial comparisons |
Arm 3 Boserolimab 30 mg Q3W + Pembrolizumab 200 mg Q3W + Pemetrexed + Carboplatin (NSCLC) vs Arm 4 Boserolimab 30 mg Q6W + Pembrolizumab 400 mg Q6W + Nab-paclitaxel (TNBC): Arm 3 and 4: Number of Participants With One or More AEs | 10 of 10 | 41 of 41 | 51 | NCT03396445 | Trial comparisons |
| Progression-free Survival Rate/KRAS Negative Group vs Progression-free Survival Rate/KRAS Mutant Group: Progression Free Survival Rate | 4 of 15 | 0 of 15 | 30 | NCT02047344 | Trial comparisons |
| Arm A-Vinorelbine vs Arm B-Pemetrexed: serious adverse events | 4 of 8 | 2 of 14 | 22 | NCT00545948 | Trial comparisons |
| 8 mg/kg TRC105 + Bevacizumab + Paclitaxel/Carboplatin vs 10 mg/kg TRC105 + Bevacizumab + Paclitaxel/Carboplatin: Percent of Patients With Progression-free Survival (PFS) at 6 Months | 1 of 3 | 7 of 10 | 13 | NCT03780010 | Trial comparisons |
| Atezolizumab vs Gemcitabine + Cisplatin/Carboplatin: deaths from any cause | 1 of 4 | 1 of 4 | 8 | NCT02409355 | Trial comparisons |
| Atezolizumab vs Gemcitabine + Cisplatin/Carboplatin: serious adverse events | 1 of 4 | 1 of 4 | 8 | NCT02409355 | Trial comparisons |
| Sapanisertib 3 mg QD vs Sapanisertib 2 mg BID: deaths from any cause | 1 of 4 | 0 of 3 | 7 | NCT05275673 | Trial comparisons |
| Sapanisertib 3 mg QD vs Sapanisertib 2 mg BID: serious adverse events | 1 of 4 | 1 of 3 | 7 | NCT05275673 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0056806/comparisons